Unicycive Therapeutics
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2016-01-01
- Employees
- 14
- Market Cap
- -
- Website
- http://www.unicycive.com
- Introduction
Unicycive Therapeutics, Inc. engages in the development of treatment for kidney diseases. Its products include UNI-494, Renazorb, and UNI-220. The company was founded by Shalabh Gupta on August 18, 2016 and is headquartered in Los Altos, CA.
A Study to Assess the Tolerability of Oxylanthanum Carbonate in Patients With Chronic Kidney Disease on Dialysis
Phase 2
Completed
- Conditions
- Chronic Kidney Disease Requiring Chronic Dialysis
- Interventions
- First Posted Date
- 2024-01-23
- Last Posted Date
- 2024-06-24
- Lead Sponsor
- Unicycive Therapeutics, Inc
- Target Recruit Count
- 106
- Registration Number
- NCT06218290
- Locations
- 🇺🇸
Clinical Advancement Center, PLLC, San Antonio, Texas, United States
🇺🇸US Renal Care, San Antonio, Texas, United States
© Copyright 2025. All Rights Reserved by MedPath